Skip to main content

Site notifications

XEOMIN Merz Australia Pty Ltd

Product name
XEOMIN
Accepted date
Apr-2024
Active ingredients
incobotulinumtoxinA
Proposed indication
For the treatment of:
• Cervical dystonia (spasmodic torticollis)
• Blepharospasm
• Spasticity of the upper limb
• Spasticity of the lower limb
• Chronic sialorrhea due to neurological disorders
• Upper facial lines
- Glabellar frown lines
- Lateral periorbital lines (crow’s feet)
- Horizontal forehead lines

For the symptomatic treatment of:
• Chronic sialorrhea due to neurological/neurodevelopmental disorders
• Spasticity of the lower and/or upper limbs
Application type
C (new indication)
Publication date
Apr-2024

Help us improve the Therapeutic Goods Administration site